1. Home
  2. LSTA vs CTXR Comparison

LSTA vs CTXR Comparison

Compare LSTA & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LSTA
  • CTXR
  • Stock Information
  • Founded
  • LSTA 1980
  • CTXR 2007
  • Country
  • LSTA United States
  • CTXR United States
  • Employees
  • LSTA N/A
  • CTXR N/A
  • Industry
  • LSTA Misc Health and Biotechnology Services
  • CTXR Biotechnology: Pharmaceutical Preparations
  • Sector
  • LSTA Health Care
  • CTXR Health Care
  • Exchange
  • LSTA Nasdaq
  • CTXR Nasdaq
  • Market Cap
  • LSTA 22.3M
  • CTXR 20.8M
  • IPO Year
  • LSTA N/A
  • CTXR N/A
  • Fundamental
  • Price
  • LSTA $2.21
  • CTXR $1.14
  • Analyst Decision
  • LSTA Strong Buy
  • CTXR Strong Buy
  • Analyst Count
  • LSTA 2
  • CTXR 3
  • Target Price
  • LSTA $23.50
  • CTXR $53.00
  • AVG Volume (30 Days)
  • LSTA 23.3K
  • CTXR 473.1K
  • Earning Date
  • LSTA 11-11-2025
  • CTXR 08-12-2025
  • Dividend Yield
  • LSTA N/A
  • CTXR N/A
  • EPS Growth
  • LSTA N/A
  • CTXR N/A
  • EPS
  • LSTA N/A
  • CTXR N/A
  • Revenue
  • LSTA $1,070,000.00
  • CTXR N/A
  • Revenue This Year
  • LSTA N/A
  • CTXR N/A
  • Revenue Next Year
  • LSTA N/A
  • CTXR $851.67
  • P/E Ratio
  • LSTA N/A
  • CTXR N/A
  • Revenue Growth
  • LSTA N/A
  • CTXR N/A
  • 52 Week Low
  • LSTA $1.87
  • CTXR $0.65
  • 52 Week High
  • LSTA $4.20
  • CTXR $15.25
  • Technical
  • Relative Strength Index (RSI)
  • LSTA 41.26
  • CTXR 39.16
  • Support Level
  • LSTA $2.11
  • CTXR $1.10
  • Resistance Level
  • LSTA $2.33
  • CTXR $1.25
  • Average True Range (ATR)
  • LSTA 0.16
  • CTXR 0.09
  • MACD
  • LSTA -0.00
  • CTXR -0.01
  • Stochastic Oscillator
  • LSTA 25.93
  • CTXR 7.45

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

Share on Social Networks: